Warfarin use in haemodialysis patients with atrial fibrillation lacks randomized efficacy data and increases the risk of haemorrhagic stroke and major bleeding.
Warfarin is commonly used to prevent stroke in patients with atrial fibrillation; however, patients on haemodialysis may not derive the same benefit from warfarin as the general population. There are no randomized controlled studies in dialysis patients which demonstrate the efficacy of warfarin in preventing stroke. In fact, warfarin places the dialysis patient at increased risk for haemorrhagic stroke and possibly ischaemic stroke. Additionally, warfarin increases the risk of major bleeding and has been associated with vascular calcification. Routine use of warfarin in dialysis for stroke prevention should be discouraged, and therapy should only be reserved for dialysis patients at high risk for thrombo-embolic stroke and carefully monitored if implemented.
Yang et al. (Tue,) conducted a review in Atrial fibrillation in haemodialysis patients. Warfarin was evaluated. Warfarin use in haemodialysis patients with atrial fibrillation lacks randomized efficacy data and increases the risk of haemorrhagic stroke and major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: